Results 241 to 250 of about 54,431 (288)

Mutational Signature‐Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian Cancer

open access: yesCancer Science, EarlyView.
A whole‐exome sequencing–based mutational signature biomarker (MSBM) identified an HRD‐enriched population in advanced ovarian cancer. In a phase II trial, olaparib maintenance suggested clinically meaningful PFS benefit without bevacizumab, supporting MSBM as a complementary HRD assessment approach.
Katsutoshi Oda   +20 more
wiley   +1 more source

Comparison of Long vs. Short Concave Neck in One‐Piece Implants Inserted 1 mm Subcrestally: A Pre‐Clinical In Vivo Study

open access: yesClinical Oral Implants Research, EarlyView.
ABSTRACT Objectives The aim was to assess the influence of one‐piece implant concave neck height on soft‐ and hard‐tissue healing on a canine model. Material and Methods Monoblock implants with a transgingival concave neck were randomly inserted 1 mm subcrestally.
Hadi Antoun   +5 more
wiley   +1 more source

Intervention outcomes of children with non‐degenerative dystonia and associated hyperkinetic movement disorders: A scoping review

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract Aim To identify the outcomes reported in published studies of intervention approaches used with non‐degenerative childhood hyperkinetic movement disorders, including dystonia, dyskinesia, hypertonia, athetosis, chorea, cerebral palsy, involuntary movement, and kernicterus, and map them to the International Classification of Functioning ...
Hortensia Gimeno   +10 more
wiley   +1 more source

Unravelling dialysis‐related dysglycaemia: Longitudinal insights from continuous glucose monitoring

open access: yesDiabetic Medicine, EarlyView.
Abstract Aim To characterise CGM‐derived glycaemic trajectories over 12months in people receiving maintenance haemodialysis, with a particular focus on hypoglycaemia burden and composite glycaemic risk. Methods We conducted a longitudinal observational study. CGM data were collected at baseline, 6 and 12 months.
Hellena Hailu Habte‐Asres   +4 more
wiley   +1 more source

Clustering of technological attitudes and reasons for device (non‐)uptake among Dutch people with type 1 diabetes, family members and health professionals

open access: yesDiabetic Medicine, EarlyView.
Abstract Background Pump and sensor technology contributes to glucose management and quality of life for people with type 1 diabetes (PWD). However, not everyone uses these technologies. This commonly relates to technological attitudes, experiences and expectations. Also, parents and partners (P/P) and healthcare providers (HCPs) may impactful decision‐
M. Horsselenberg   +4 more
wiley   +1 more source

Comparative Evaluation of Supplementary Cleaning Techniques for Removal of Bio-C Sealer and AH-Plus from Oval Root Canals: A Micro-CT Analysis. [PDF]

open access: yesIran Endod J
Bincelli Seckler IN   +5 more
europepmc   +1 more source

Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Semaglutide, a GLP‐1 receptor agonist, has demonstrated significant weight loss benefits for patients with overweight or obesity in both oral and subcutaneous (s.c.) formulations. Given comparable systemic exposure between formulations, an indirect treatment comparison (ITC) was conducted to confirm comparable efficacy.
Molly Plotkin   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy